AGA 2118
Alternative Names: AGA-04; AGA-2118Latest Information Update: 23 Feb 2024
At a glance
- Originator Angitia
- Class Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Osteoporosis
Most Recent Events
- 13 Jan 2024 Angitia Biopharmaceuticals completes phase-I trial in Osteoporosis (In adults, In the elderly, In volunteers) in Australia (IV) (NCT05225857)
- 13 Jan 2024 Angitia Biopharmaceuticals completes phase-I trial in Osteoporosis (In adults, In the elderly, In volunteers) in Australia (SC) (NCT05225857)
- 28 Jun 2022 Phase-I clinical trials in Osteoporosis (In adults, In the elderly, In volunteers) in Australia (IV) (NCT05225857)